Tuesday 21st November 2023
|Text too small?|
AFT Pharmaceuticals (ASX: AFP, NZX: AFT ) today announces its first aid antiseptic cream Crystaderm has been approved for sale in China, the world’s second largest healthcare market.
The registration by China’s relevant government agency will allow the medicine to be sold in China. Currently AFT sells the medicine into China via its Cross Border E-Commerce (CBEC) site on Tmall China.
AFT Managing Director Dr Hartley Atkinson says: “We are delighted with the approval of this medicine and excited about the growth opportunities it opens for the company. This is consistent with our International expansion plans.
“Crystaderm is one of our most popular products in New Zealand and is a key focus on our Tmall site. We believe it has the potential for success in Chinese E-commerce sites and over the counter medicine outlets. We are still firming up plans for the distribution of this medicine in China, but we expect it to be launched in the market in the 2024 calendar year.”
Crystaderm is a preservative-free first aid cream used for the treatment and prevention of minor skin infections such as acne, cuts, scrapes, grazes, burns and school sores (impetigo). Unlike topical antibiotics it carries no known risk of bacterial resistance and consequently in New Zealand has been widely prescribed by doctors. Hydrogen peroxide, its active ingredient, is a potent agent against many types of bacteria. The medicine is designed to melt at skin temperature and to release the active ingredient to both moist and dry areas, and doesn’t stain skin, hands, or fabric.
Released for and on behalf of AFT Pharmaceuticals limited by Malcolm Tubby, Chief Financial Officer.
For more information:
Dr Hartley Atkinson Richard Inder
Managing Director The Project
AFT Pharmaceuticals Tel: +64 21 645 643
Tel: +64 9488 0232
About AFT Pharmaceuticals www.aftpharm.com
AFT Pharmaceuticals are a growing multinational pharmaceutical company that develops, markets, and distributes a broad portfolio of pharmaceutical products across a wide range of therapeutic categories which are distributed across all major pharmaceutical distribution channels: over the counter, prescription, and hospital. AFT Pharmaceutical's product portfolio comprises both proprietary and in-licensed products, and includes patented, branded, and generic drugs.
No comments yet
DOW - Refinance of Syndicated Sustainability Linked Loan facility
OCA - Appointment of Chief People Officer
CHI - Director changes at Channel Infrastructure
December 6th Morning Report
December 5th Morning Report
TWR - Tower announces strategic review
PFI - 11 Sheffield Street, Blenheim Divestment
December 4th Morning Report
Me Today - Notice of Annual Shareholder Meeting
FSF - Director Scott St John to retire from Fonterra Board